comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 10:04:23 - browse：62598

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Health AI adoption puts security, privacy startups on investors' radar

WSS

Health Care Service Corp to buy Cigna Medicare Advantage plans

Medicare drug price negotiation legal challenge met with skepticism

Why you shouldn’t ask, “What country has the best health care?”

Positive childhood experiences can help future health

Bernie Sanders is gearing up to subpoena pharma CEOs

Health AI adoption puts security, privacy startups on investors' radar

knowledge

comprehensive

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Zyn nicotine pouches become unlikely player in latest culture war

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Bluebird, CVS, Contineum

Bright Health sells Medicare Advantage business to Molina

Medicare drug price negotiation legal challenge met with skepticism

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

SCOTUS questions limit to govt efforts to fight misinformation

23andMe had bad news about my health. I wish a person had delivered it

Stop the failed accountable care organization experiment

knowledge

Gene editing the human germline: What are the risks?

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Merck, Johnson & Johnson CEOs will testify on high drug prices

Nurses recount patients attacks

UnitedHealth increases loan offers after Change Healthcare outage

Medicare drug price negotiation legal challenge met with skepticism

focus

focus

explore

focus